Fig. 2.

Main study endpoints in the group of women with oral contraceptive-induced menstrual migraine (OCMM) treated with frovatriptan (open bars) and the comparators (grey bars). Data are reported as relative (%) frequencies for pain free (PF) at 2 and 24 h, for pain relief (PR) at 2 and 24 h, and for relapses at 24 and 48 h. The p values on top of the bars refer to the level of the statistical significance of the difference between the two study drugs